Thursday, 2 April 2020

Blood Testing Market Volume Forecast And Value Chain Analysis 2019

Global Blood Testing Market Research Report: By Test Type (Complete Blood Count, Blood Chemistry Tests, Enzyme Tests), Disease (Anemia, Infection, Leukemia,), Method (Manual, Automated), End-User (Hospitals, Diagnostic Center) – Global Forecast Till 2023
Market Scenario:
Blood Testing is a laboratory analysis technique that is performed based on the blood sample taken from patient's body through a finger prick or syringes to determine the state of the health. The abnormal functioning of organs can be determined by Blood Testing. These tests are affordable and are commonly performed in hospitals and clinics as a primary checkup for identifying any mild to serious ailments which influence the growth of the Blood Testing market.
The Global market for Blood Testing is expected to grow at a CAGR of approximately 5.5% during 2017 to 2023.
Key Players:
The global blood Testing market is led by some of the fervent players including Baxter International (US), Abbott Laboratories Inc. (US), Gen-Probe, Inc. (US), Becton Dickinson & Company (US), Novartis Diagnostics (US), Biomerica, Inc. (US), Cepheid Corporation (US), Meridian Bioscience, Inc. (US), Trinity Biotech (US), Siemens Healthcare (Germany), Bio-Rad Laboratories Inc. (US), Grifols (Spain), bioMérieux (France), Nanosphere Inc. (US), Roche Diagnostics (Switzerland), Bruker Corporation (US), Alere Inc. (US), Thermo Fisher Scientific Inc. (US) Cardinal Health (US), Beckman Coulter (US), Danaher Corporation (US), and Trividia Health (US)
Industry, Innovation & Related News
September 07, 2018 – Scientists in Australia published their study of a novel blood test they have developed in the JCI Insight Journal. The new blood test that can potentially identify whether a person who had a heart attack in the past is at high risk of having another one. certain lipid biomarkers or fats in the blood to improve upon traditional risk factors in predicting heart disease. The researchers hope to trial it in Australia in the next two to three years.
August 13, 2018 – Engineering for All (Israel), announced the development of a handheld programmable device, named as RevDx (Revolution Diagnostics) that performs automated blood analysis and diagnostics at the point of care. RevDx is meant for anyplace without reliable access to a lab, electricity or Internet connection.
Market Drivers
Growing incidents of chronic diseases and conditions such as cancer, diabetes, heart disease along with the organ failure cases drive the demand for blood testing in multiplications. Needless to say, that the blood testing market is ever increasing. Also, great technological strides being made in electronic monitoring devices and substantial investments transpired into R&D activities are in turn, paying off well, expanding the market size.
Additional factors supporting the market growth include the ever-increasing population that is getting inclined towards the sedentary lifestyle and urbanization. Improving economic conditions are rapidly availing access to the excellent health care, increasing the healthcare expenditures and eventually the market growth.
Conversely, lack of awareness towards the availability and advantages of blood testing is obstructing the market growth.  Also, the unmet clinical needs coupled with the unavailability of external funding; especially in the developing regions are obstructing the market growth. Nevertheless, increasing demand for personal & hand-held diagnostic devices & augmenting demand for the blood testing in the diagnostics that can give fastest & accurate results is fostering the market growth.
Segmentation
The global Blood Testing market has been segmented on the basis of test type, disease, method, and end-user.
On the basis of test type, the global Blood Testing market can be segmented into glucose testing, lipid panel testing, direct LDL testing, Prostate Specific Antigen (PSA) testing, Blood Urea Nitrogen (BUN) testing, A1C testing, high sensitivity C-Reactive Protein (hs-CRP) testing, Vitamin D testing, alt testing, thyroid stimulating hormone testing, creatinine testing, serum nicotine/cotinine testing, AST testing, cortisol testing, testosterone testing, and others.
On the basis of disease, the global Blood Testing market can be segmented into anemia, infection, leukemia, hypokalemia, kidney disorders, heart attack, coronary heart disease, and other diseases.
On the basis of method, the global Blood Testing market can be segmented into manual blood culture testing and automated blood culture testing.
The automated blood culture testing segment is classified into automated blood culture system, blood culture instruments, and others      
On the basis of end-user, the global Blood Testing market is segmented into hospitals, clinics, diagnostic centers, research labs, and others.
Regional Analysis                     
The global Blood Testing market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global Blood Testing market owing to the rising incidence of diseases such as kidney disorders, blood stream infections, other infections, high demand for rapid diagnostic tests, and growing aging population.
The European Blood Testing market is the second largest market owing to the increasing awareness of chronic infection diseases due to the initiatives undertaken by private companies, government organizations, and educational institutions.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to the increasing awareness of the importance of diagnostics in personalized medicines and due to government initiatives, that promote the use of personalized medicines. Furthermore, the increase in a number of government schemes to curb the rising healthcare expenditures in emerging economies is expected to drive the regional market growth.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Competitive Analysis
The blood testing market appears fragmented and fiercely competitive due to many large and small players churning the competition in the market.  Through the strategic partnership, acquisition, expansion, product & technology launch, and collaboration, these players try to gain the competitive edge.
Posted by at No comments:
Labels:

Chordoma Disease Market To Observe Strong Development By 2019

Global Chordoma Disease Market Research Report: By Diagnosis (Biopsy, Imaging, Blood Tests), Treatment (Chemotherapy, Radiation Therapy, Cryosurgery, Surgery, Targeted Therapy), End-User (Hospital, Clinic, Cancer Care Centers) – Global Forecast Till 2023
Market Scenario
Chordoma is a rare, slow-growing type of bone cancer. The increasing awareness programs about cancers led by WHO and UNICEF and the rising healthcare investment in the emerging markets are anticipated to exhibit more opportunities for the growth of the chordoma disease market trends.
The global chordoma disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global chordoma disease market is segmented into biopsy, imaging, blood tests, and others. The imaging segment is further divided into x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scanning, and bone scan.
On the basis of treatment, the global chordoma disease market is segmented into chemotherapy, radiation therapy, cryosurgery, surgical treatments, radiosurgery, targeted therapy, and others. The surgery segment is further classified into radical resections, sacral chordoma, spinal chordoma, skull base chordoma, and others. The chemotherapy segment is classified into methotrexate, doxorubicin, and others. Furthermore, the targeted therapy segment is divided into bevacizumab, erlotinib, and others.
On the basis of end-user, the global chordoma disease market is segmented into hospitals, clinics, cancer care centers, and others.
Regionally, the Americas chordoma disease market is segmented into two major regions, namely, North America and South America.
The Americas region holds the largest share of the global chordoma disease market owing to the increasing demand for targeted therapies and growing health concerns. As per an estimate by the American Cancer Society, about 3,300 new cases of bone cancer were diagnosed in 2016 with a death toll of about1490. Thus, the high prevalence of chondroid chordomas is the major hurdle in the market growth.
Key Players
Some of the key players in the global chordoma disease market are AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Debiopharm Group (Switzerland), Bayer AG (Germany), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), ProCure Treatment Centers, Inc. (U.S.), Varian Medical Systems, Inc.(U.S.), Amura Holdings Ltd. (U.S.), Catena pharmaceuticals Inc. (U.S.), Celldex therapeutics Inc. (U.S.), Eckert & Ziegler BEBIG (Germany), Infinity Pharmaceuticals (U.S.), Medivir AB (Sweden), Merrion Pharmaceuticals Plc. (U.S.), and others.
Regional Analysis                    
The global chordoma disease market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global chordoma disease market owing to the high prevalence of bone cancer in the region and aging population, along with high favorable reimbursement policies in the region. As per the American Cancer Society in 2017, about 3,260 people are projected to be diagnosed with primary bone cancer in the U.S. (1,820 men and boys and 1,440 women and girls).
The European chordoma disease market is anticipated to emerge as the second largest market owing to the development of the pharmaceutical and medical industries. According to the Cancer Research U.K. organization in 2014, about 580 new cases of bone sarcoma were found in the U.K.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to less awareness regarding bone cancer among the population and less availability of effective treatment option for bone cancer in the region. For instance, in September 2016, Dr. Reddy's Laboratories entered into a strategic collaboration with Amgen for marketing and distributing Prolia (denosumab), Vectibix (panitumumab), and Xgeva (denosumab) in India.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Posted by at No comments:

Retropharyngeal Abscess Market Value Share, Supply Demand, Share And Value Chain 2019

Market scenario:
Retropharyngeal abscess is a serious infection deep in the neck and generally occurs in children under age eight, though it can also affect adults. The symptoms include difficulty in breathing and swallowing, pain, severe cough and throat pain, neck stiffness and spasms and others. If left untreated, retropharyngeal abscess infection can result in septic shock, organ failure and death. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications.
The Latest report by Market Research Future (MRFR) asserts that, The global retropharyngeal abscess market is expected to reach USD 5.9 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.5 % during the forecast period 2017-2023.
The market drivers include rise in demand due to growing young and immune-compromised population, increasing screening, and others. The market restraints are the complications such as risk of bleeding, pain, especially during surgery, high cost of treatment, poor healthcare penetration and others.
Development of antibiotics resistant bacteria is the single most unmet need of the market. Product development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to development of selective gram negative antibiotics. Market development is another strategy for as there is a large unmet need in the developing regions such as India and China. Cost of the product will be a decisive factor in the developing regions such as Asia Pacific and especially Africa.
Key Players
  • Merck KGaA,
  • Johnson & Johnson,
  • AstraZeneca plc,
  • Sanofi S.A.,
  • Pfizer,
  • Mylan N.V,
  • Novartis AG,
  • Teva pharmaceutical company,
  • GlaxoSmithKline plc.
Segments
The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.
Based on the diagnosis, the market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.
Based on the treatment, the market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.
Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.
Regional Analysis
Asia Pacific retropharyngeal abscess market size is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region. However the low expenditure on healthcare coupled with the poor incomes in the developing regions is a dent on the market.
A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the retropharyngeal abscess market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retropharyngeal abscess market in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.
Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.
Posted by at No comments:

Hypersensitivity Pneumonitis Market To Observe Strong Development By 2019

Market Synopsis of Global Hypersensitivity Pneumonitis Market
Hypersensitivity pneumonitis is a complex syndrome caused due to exposure to a variety of organic particles. Hypersensitivity pneumonitis is divided into three types, acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis which is based on the based on the duration of the illness. According to the American Academy of Allergy, Asthma & Immunology (2013), 10%-30% of the global population suffers from allergic rhinitis. Increasing prevalence of patients suffering from hypersensitivity pneumonitis, and increasing pollution have boosted the growth of the market. Additionally, According to the American Academy of Allergy, Asthma & Immunology, in 2013, globally, sensitization rates to one or more common allergens among school children is approximately 40%-50% and in 2012, 10.6% children were diagnosed with respiratory allergies. Moreover, increasing prevalence of respiratory diseases, increasing healthcare expenditure, and strong government support for research & development have also contributed to the growth of the market. Rising geriatric population also supports the growth of the market. However, lack of long term treatment and awareness about the diseases may lead to slow the growth of the market.
The global hypersensitivity pneumonitis market is segmented on the basis of types, therapy, and end users.
On the basis of types, the market is segmented into acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis.
On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest lung function tests, X-ray, lung biopsy, and others. Treatment is further classified into pharmacological and non-pharmacological. Pharmacological is further segmented into corticosteroid therapy, immunosuppressive therapy and others.
On the basis of end users, the market is segmented into hospital, clinics, and others.
Global Hypersensitivity Pneumonitis Market   - Regional Analysis
America commands the largest market for hypersensitivity pneumonitis majorly due to increasing patient population. According to the Asthma and Allergy Foundation of America, in 2015, nasal allergies affect about 50 million people in the United States of which 30 % are adults and 40 % are children. Additionally, peanut is the most common allergen followed by milk and shellfish. In 2015, 4.2 million children in the US have food allergies. Changing environment condition, and increasing government support have supported the market growth.
On regional basis, the Americas Hypersensitivity pneumonitis market is segmented into two major regions, North America and South America. North America commands the largest market in this region. North America is further segmented into the US and Canada. High healthcare spending, increasing prevalence of the respiratory diseases and government encouragement will boost the market in North America. However, South America shows the fastest growth for the American market owing to the presence of huge opportunities for the development of the market.
The Americas hypersensitivity pneumonitis market is segmented on the basis of types, therapy, and end users. On the basis of types, the market is segmented into acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis. On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest lung function tests, X-ray, lung biopsy, and others. Treatment is further classified into pharmacological and non-pharmacological. Pharmacological is further segmented into corticosteroid therapy, immunosuppressive therapy and others. On the basis of end users, the market is segmented into hospital, clinics, and others.
Europe is the second largest market for hypersensitivity pneumonitis, which is followed by Asia Pacific. Availability of funds for research, changing environment conditions and government support for research & development will drive the market.
Asia Pacific is expecting fastest growth for the market due to the presence of a huge patient population, presence of huge opportunity in the market, and huge geriatric population. India and China are the major contributors for the market. According to the WHO in 2013, approximately 20-30% of Indian population suffers from at least one allergic disease and 8.7% of the total china’s population suffers from allergic rhinitis. Increasing prevalence of diseases have boosted the growth of the Asia Pacific market.
On the other hand, the Middle East & Africa holds the least share in the global hypersensitivity pneumonitis market due limited development in the healthcare sector and poor economy in Africa region. Majority of the market of this region is held by the Middle East due to huge healthcare spending.
Posted by at No comments:

Cubital Tunnel Syndrome Market To Observe Strong Development By 2019

Market Scenario:

Cubital tunnel syndrome is a condition of increased pressure on the ulnar nerve in the elbow. The ulnar nerve controls muscles and feeling in the hand. Furthermore, it can be caused by direct pressure, stretching, or decreased blood flow to the ulnar nerve. According to the WHO (2014), the incidence of carpal tunnel syndrome is >3 new cases per 1000 persons every year. Women are 3-4 times more susceptible than men. Increasing prevalence of the cubital tunnel syndrome is the major driving factor for the growth of the market. Moreover, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, geriatric population is more likely to suffer from this disease; According to the Aging World in 2015, 562 million (or 8.0 %) were aged 65 and over across the globe, this has increased the prevalence of the diseases and contributed to the growth of the market. However, lack of awareness among people and high cost of surgeries may restrain the growth of the market.
The global cubital tunnel syndrome market is expected to grow at a CAGR of 5.6% during forecast period 2017-2023. 
Intended Audience
  • Biotechnological institutes
  • Pharmaceutical companies
  • Government and Private Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Medical Research Laboratories 
Segmentation
The global cubital tunnel syndrome market is segmented on the basis of causes, treatment, and end users.
On the basis of causes, the market is segmented into injury, noncancerous fatty tumors, bone tumors, inflammation, and others.
On the basis of treatment, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into nerve compression tests, X-ray, electrodiagnostic studies, MRI, and others. The therapy is further segmented into non-operative, and operative. The non-operative is further classified into NSAIDs and steroids.On the basis of end users, the market is segmented into hospital, retail pharmacy, and other. 
Regional Analysis
The Americas dominates the global cubital tunnel syndrome market owing to large patient population. Additionally, increasing geriatric population, changing lifestyle, and increasing healthcare expenditure have boosted the growth of the market in America. According to the Population Reference Bureau, the number of Americans ages 65 and over is projected to be more than double from 46 million in 2016 to over 98 million by 2060. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.
Europe is the second largest cubital tunnel syndrome market, which is followed by Asia Pacific. Huge geriatric population, availability of funds for research, and government support for research & development projected to drive the market in Europe.
Asia Pacific is the fastest growing region in the global market due to the presence of a increasing patient population, continuously developing economies, and increasing need for the better treatment. According to the WHO report published in 2015, Asia's elderly population is projected to reach nearly 923 million by 2050.
Whereas, the Middle East & Africa owns the least share of  the global cubital tunnel syndrome market due to the presence of poor economy, especially, in Africa region. The market of this region is dominated by the Middle East due to well-developed healthcare sector and huge healthcare expenditure.
Posted by at No comments:

Acromegaly Market In Depth Study And Analysis Published, 2019

The major driving factors for the market are increasing prevalence of acromegaly, changing lifestyle, and increasing genetic incident of genetic diseases. Moreover, increasing prevalence of hormonal diseases, for instance, endocrine diseases, and hypopituitarism, increasing government support and rapid developments in technology have fuelled the growth of the market. On the other hand, surgical costs is high, which ranges from approximately USD 2,800 to USD 9,200, however, when averaged it is less than the cost of medications. Unavailability of precise treatment and high cost of the surgery may restrain the growth of the market.
The global acromegaly market is expected to grow at a CAGR of ~5.2 % during the forecast period 2017-2023.
Acromegaly is a hormonal disorder that results from heavy secretion of growth hormones (GH) in the body. The pituitary gland in the brain, secretes GH. In acromegaly, the pituitary produces excessive amounts of GH. Usually the excess GH comes from benign, or noncancerous, tumors on the pituitary. These benign tumors are called adenomas. Acromegaly is one of the rare diseases, which most often diagnosed in the middle-aged adults and affects 5-8 people per 1 lakh people. If the diseases is not treated, it can result in serious illness and premature death. The most serious health consequences of the disease may result into high blood pressure, type 2 diabetes, increased risk of cardiovascular disease, arthritis, and others.
Key Players
  • Novartis AG (Switzerland),
  • Aegis Therapeutics LLC (US),
  • Chiasma Inc (US),
  • Crinetics Pharmaceuticals Inc (US),
  • Daewoong Pharmaceutical Co Ltd (South Korea),
  • Peptron Inc (South Korea),
  • Silence Therapeutics Plc (UK),
  • Strongbridge Biopharma plc (US),
  • Amryt Pharma plc (UK),
  • Foresee Pharmaceuticals LLC (US),
  • Glide Pharmaceutical Technologies Ltd (US),
  • Ionis Pharmaceuticals Inc (US),
  • Ipsen SA (France)
Segmentation
Acromegaly market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of treatment, the market is segmented into medications, surgery, radiation therapy, and others. The medication is further segmented into somatostatin analogues, dopamine agonists, growth hormone receptor antagonists, and others. The surgery is further segmented into endonasal transphenoidal surgery, and transphenoidal surgery.
On the basis of diagnosis, the market is segmented into medical imaging, medical laboratory investigations, others. The medical imaging is further segmented into radiography, magnetic resonance imaging (MRI), nuclear medicine, ultrasound, and others.
On the basis of type, the market is segmented into ectopic acromegaly, acromegaly due to growth hormone, and others.
Regional Analysis
Asia Pacific is the fastest growing acromegaly market. China, and India are the significant contributors to the market growth due to the presence of huge population base, increasing prevalence of acromegaly, rapidly growing healthcare sector, and increasing healthcare expenditure. Whereas, the Middle East & Africa holds the least Acromegaly Market share of the global market due to poor economic condition and limited availability of medical facilities in African region. The Middle East & African acromegaly market is majorly driven by the UAE, Saudi Arabia, and Kuwait.
The Americas commands the global market owing to increasing prevalence of acromegaly, large patient population, high healthcare spending, and strong government support for research & development. According to the Health Research Funding Organization, in America, over 3,000 new cases of acromegaly occurs per year.
Europe leads the second position of the global the market, which is followed by Asia Pacific. High healthcare expenditure, well developed healthcare sector, and increasing government support drives the growth of the market.
Posted by at No comments:

Oral Thrush Market Trends, Analysis And Review During 2019 To 2023

Market Scenario
Oral thrush also called as oral candidiasis is an infection of the mouth caused by strains of the Candida species. Candida albicans is the most commonly implicated organism, which occurs naturally in about 50% of the world's population as a normal component of the oral microbiota. However, Candida albicans is an opportunistic pathogen and it accounts for about 50% of oral candidiasis cases across the globeand  other strains of candida such as C. tropicalis, C. glabrata and C. albicans, account for over 80% of cases collectively. Increasing prevalence of  HIV has increased immunodeficiency in the patient, which makes the patient more susceptible to dubliniensis and C. geotrichium. Furthermore, the infection is also detected in hospitalized patients, smokers, immune-compromised individuals due to diseases such as diabetes, cancer, and Down syndrome.
Apart from common Oral Thrush symptoms such as white layer of infection on the tongue and other parts of oral mucosa, it includes burning sensation, metallic, acidic, salty or bitter taste in the mouth, difficulty swallowing (dysphagia), and hoarseness of the voice etc.
Various factors affects the prevalence of Candida such as high humidity, and temperature. Females are more prone to develop the condition as compared to males. Moreover, people wearing dentures, consumption of high  carbohydrates containing diet, suffering from xerostomia (dry mouth) are at a higher risk of developing oral thrush. Other factors affecting the market for oral thrush is age with newborns and aged population having the least prevalence while infants having the highest.
Market development represents the best strategy for the market growth. The market will witness exponential growth over the review period owing to advanced antibacterial mouth rinses and improving palatability and quality of oral hygiene products. The developing regions of Asia and the Middle East are attracting new players owing to less regional competition for the oral thrush product. Increase in risk factors such as high fat containing and sugar rich foods, growing screening, increasing infant population. On the other hand, the market may experience a slow growth on account of lack of awareness and misdiagnosis of the disease.
The global oral thrush treatment market is expected to reach USD 9.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.
Key Players in the Global Oral Thrush Market
Some of key players profiled in the report are Bayer AG, Teva Pharmaceuticals, Stellar Pharma, Pfizer Inc., Wockhardt Ltd., Ranbaxy Laboratories Limited, Bristol Laboratories, Glenmark Pharmaceuticals, GlaxoSmithKline Plc., and others.
Segmentation:
The global oral thrush market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on type, the market has been segmented as pseudomembranous, erythematous, hyperplastic, and others.
Based on diagnosis, the market has been segmented as examination, biopsy, endoscopy, and others.
Based on treatment, the market has been segmented as anti-fungal, immune-modulators, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Regional Analysis
Globally, the North America market dominates the Oral Thrush market. Factors such as the well-spread awareness among people towards the oral hygiene and healthcare along with the extensive use of medications and high expenditure on the health care and augmenting uptake of new products primarily in the US drive the market growth in the region.
The Europe market accounts for the second-largest market for Oral Thrush owing to the proliferation of healthcare sector, the presence of well-established players and growing healthcare expenditures in the region. Indeed, the resurging economy is the main driving force increasing the market value in the region.
Simultaneously, the presence of the leading global players in the region is some of the key factor substantiating the growth of the regional market. Witnessing a widening uptake of oral hygiene products across the region, the North America market for Oral Thrush is likely to continue its dominance throughout the assessment period.  The North American market significantly contributing to the GDP is expected to register a significant CAGR during the forecast period.
The Europe healthcare industry is currently booming given the increasing number of medical professionals and growing awareness in the region. Moreover, the high influence of media and the rise in the awareness regarding oral hygiene especially in the countries such as Germany and France drive the European oral thrush market.
The Asia Pacific Oral Thrush market emerging as the fastest growing market accounts for a substantial market share on the global platform. Factors such as the proliferation of healthcare sector in populous countries such as India and China substantiate the market growth in the region. 
Furthermore, factors such as augmenting demand for high standards and high-quality oral care products along with the growing technological advancement are estimated to increase the market scope, boosting the demand for effective oral care treatments in the region.
Posted by at No comments:
Subscribe to: Posts (Atom)